The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Publication
, Journal Article
Wilke, RA; Ramsey, LB; Johnson, SG; Maxwell, WD; McLeod, HL; Voora, D; Krauss, RM; Roden, DM; Feng, Q; Cooper-Dehoff, RM; Gong, L; Klein, TE ...
Published in: Clin Pharmacol Ther
July 2012
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
July 2012
Volume
92
Issue
1
Start / End Page
112 / 117
Location
United States
Related Subject Headings
- Simvastatin
- Risk Factors
- Risk Assessment
- Precision Medicine
- Polymorphism, Single Nucleotide
- Pharmacology & Pharmacy
- Pharmacogenetics
- Organic Anion Transporters
- Muscular Diseases
- Liver-Specific Organic Anion Transporter 1
Citation
APA
Chicago
ICMJE
MLA
NLM
Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., … Clinical Pharmacogenomics Implementation Consortium (CPIC), . (2012). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther, 92(1), 112–117. https://doi.org/10.1038/clpt.2012.57
Wilke, R. A., L. B. Ramsey, S. G. Johnson, W. D. Maxwell, H. L. McLeod, D. Voora, R. M. Krauss, et al. “The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.” Clin Pharmacol Ther 92, no. 1 (July 2012): 112–17. https://doi.org/10.1038/clpt.2012.57.
Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112–7.
Wilke, R. A., et al. “The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.” Clin Pharmacol Ther, vol. 92, no. 1, July 2012, pp. 112–17. Pubmed, doi:10.1038/clpt.2012.57.
Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M, Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112–117.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
July 2012
Volume
92
Issue
1
Start / End Page
112 / 117
Location
United States
Related Subject Headings
- Simvastatin
- Risk Factors
- Risk Assessment
- Precision Medicine
- Polymorphism, Single Nucleotide
- Pharmacology & Pharmacy
- Pharmacogenetics
- Organic Anion Transporters
- Muscular Diseases
- Liver-Specific Organic Anion Transporter 1